Intraoperative Collection of Ascitic Fluid With Intra- or Postoperative Reinfusion in Ovarian Cancer: Safety and Feasibility of a Roller Pumping Method.

INTRODUCTION Patients with ovarian cancer often present with massive ascites, leading to significant protein loss during surgical procedures. Although cell-free concentrated ascites reinfusion therapy (CART) is used in palliative settings to mitigate protein loss, its application in intraoperative settings remains unexplored. METHODS We retrospectively evaluated patients who underwent intraoperative CART for ovarian cancer treatment between March 2022 and 2025, compared two ascitic fluid collection methods (syringe and roller pumping), and analyzed operative parameter, fluid collection efficiency, albumin recovery, and adverse event-related data. RESULTS Among the 12 patients included in this study, seven (58.3%) underwent CART using the roller pumping method, which significantly reduced the collection time compared with the syringe method (9 vs. 22 min, p < 0.05). The median collection speed was also significantly higher with the roller pumping method (404 vs. 140 mL/min, p < 0.05). Approximately 70% of the albumin in the collected ascitic fluid was successfully reinfused. Adverse events included transient hypotension (16.7%) and hypertension (25.0%), both of which resolved without intervention. CONCLUSION Intraoperative CART is a feasible and safe technique for protein loss management in patients undergoing surgery for ovarian cancer. The roller pumping method significantly shortened ascites collection time and reduced surgical burden.

• Publication year

  2026

• Venue

  Therapeutic apheresis and dialysis

• Publication date

  2026-02-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1744-9987.70123PMID 41655992
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients

  2025cited by this paper
• Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience

  2022cited by this paper
• Quality of life assessment of cell‐free and concentrated ascites reinfusion therapy during initial treatment for advanced ovarian cancer: A prospective cohort study

  2021cited by this paper
• The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer

  2021cited by this paper
• The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis

  2021cited by this paper
• Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.

  2020cited by this paper
• Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience

  2020cited by this paper
• Perioperative Quality Initiative consensus statement on intraoperative blood pressure, risk and outcomes for elective surgery

  2019cited by this paper
• Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites

  2018cited by this paper
• Prognostic significance of preoperative serum albumin in epithelial ovarian cancer patients: a systematic review and dose–response meta-analysis of observational studies

  2018cited by this paper
• Clinical statistics of gynecologic cancers in Japan

  2017cited by this paper
• Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study.

  2017cited by this paper
• Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results

  2017cited by this paper
• Multivariate analysis of risk factors for cisplatin‐induced nephrotoxicity in gynecological cancer

  2017cited by this paper
• Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.

  2016cited by this paper
• Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

  2015cited by this paper
• Clinical usefulness of concentrated ascites reinfusion therapy (CART) for gynecological cancer patients with refractory massive ascites due to cancerous peritonitis.

  2014cited by this paper
• PleurX Peritoneal Catheter Drainage System for Vacuum-Assisted Drainage of Treatment-Resistant, Recurrent Malignant Ascites

  2012cited by this paper
• Albumin infusion in patients undergoing large‐volume paracentesis: A meta‐analysis of randomized trials

  2012cited by this paper
• Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives

  2011cited by this paper
• Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

  2010cited by this paper
• Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

  2009cited by this paper
• Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

  2009cited by this paper
• Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites.

  1990cited by this paper
• Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.

  1988cited by this paper

• No citing papers are available for this paper.